| enGene to Participate in Upcoming Investor Conferences |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday,. |
businesswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price. |
businesswire.com |
2025-04-04 12:00:00 |
Czytaj oryginał (ang.) |
| enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Stifel 2025 Virtual Targeted Oncology Forum, on Tuesday, April 8, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene e. |
businesswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| enGene Reports First Quarter 2025 Financial Results and Provides Business Update |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. “With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our plan to file a BLA for detalimogene in mid-2026,” said Ron Cooper, Chief Executive Officer o. |
businesswire.com |
2025-03-10 18:05:00 |
Czytaj oryginał (ang.) |
| enGene Holdings Inc.: Unknown Company Which Looks Like A Catch |
enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene voraplasmid, enGene's lead asset, shows high complete response rates in BCG-unresponsive NMIBC patients, positioning it as a viable monotherapy option. Financials reveal a market cap of $320mn and a cash runway of 14–17 quarters, indicating undervaluation compared to market potential. |
seekingalpha.com |
2025-02-27 06:20:04 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for February 19th |
NVMI, FRSH and ENGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 19, 2024. |
zacks.com |
2025-02-19 13:15:39 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for February 19th |
GE, OPRT, ENGN, FRSH and NVMI have been added to the Zacks Rank #1 (Strong Buy) List on February 19, 2024. |
zacks.com |
2025-02-19 08:35:21 |
Czytaj oryginał (ang.) |
| enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today reported the grant of inducement equity awards to. |
businesswire.com |
2025-01-31 18:05:00 |
Czytaj oryginał (ang.) |
| enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today announced three poster presentations at the 2025. |
businesswire.com |
2025-01-30 10:00:00 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in enGene Holdings Inc. (ENGN)? Wall Street Analysts Think 238.77% |
The average of price targets set by Wall Street analysts indicates a potential upside of 238.8% in enGene Holdings Inc. (ENGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-01-09 12:56:15 |
Czytaj oryginał (ang.) |
| enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today reported the grant of inducement equity awards to. |
businesswire.com |
2024-12-30 18:05:00 |
Czytaj oryginał (ang.) |
| enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why |
enGene Holdings Inc. (ENGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2024-12-20 15:01:19 |
Czytaj oryginał (ang.) |
| enGene Reports Full Year 2024 Financial Results and Provides a Business Update |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), announced its financial results for the full year end. |
businesswire.com |
2024-12-19 18:05:00 |
Czytaj oryginał (ang.) |
| enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook |
enGene is working toward an approval similar to what IBRX got with Anktiva, although without needing BCG co-administration. NMIBC remains an area of unmet need, although it may not be SO unmet that the FDA gives ENGN a generous approval on single-arm data. Considering the current price, and their favorable financial position, my outlook from here for the company is very positive. |
seekingalpha.com |
2024-12-15 06:53:23 |
Czytaj oryginał (ang.) |
| Here's Why enGene Holdings Inc. (ENGN) is Poised for a Turnaround After Losing -16.9% in 4 Weeks |
enGene Holdings Inc. (ENGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-12-13 12:35:24 |
Czytaj oryginał (ang.) |
| enGene to Participate in Upcoming Investor Conferences |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Alex Nichols, Ph.D., Chief Strategy. |
businesswire.com |
2024-11-25 10:00:00 |
Czytaj oryginał (ang.) |
| enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Ron Cooper, Chief Executive Officer. |
businesswire.com |
2024-11-05 10:00:00 |
Czytaj oryginał (ang.) |
| enGene Announces $60 Million Private Placement Financing |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of. |
businesswire.com |
2024-10-25 12:00:00 |
Czytaj oryginał (ang.) |
| enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today reported the grant of an inducement equity award t. |
businesswire.com |
2024-10-22 20:05:00 |
Czytaj oryginał (ang.) |
| enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of Joan Connolly as Chie. |
businesswire.com |
2024-10-21 12:45:00 |
Czytaj oryginał (ang.) |
| enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today reported the grant of inducement equity awards to. |
businesswire.com |
2024-10-01 20:05:00 |
Czytaj oryginał (ang.) |
| Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis). Today, the Company announced preliminary data from 21. |
businesswire.com |
2024-09-26 10:30:00 |
Czytaj oryginał (ang.) |
| enGene to Participate in Upcoming Investor Conferences |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that the Company will participate in several upcoming inv. |
businesswire.com |
2024-08-28 20:05:00 |
Czytaj oryginał (ang.) |
| enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the second quarter ended April 30, 2024, and provided a business update. “Our $200 million private placement in February positioned us well to execute our p. |
businesswire.com |
2024-06-14 11:01:00 |
Czytaj oryginał (ang.) |
| enGene to Present at the Jefferies Global Healthcare Conference |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present a corporate overview at the Jefferies Global Healthcare Conference in New York City, on June 5, 2024, at 12:30 p.m. ET. A live webcast of the presentation can. |
businesswire.com |
2024-05-29 11:30:00 |
Czytaj oryginał (ang.) |
| enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors |
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serv. |
businesswire.com |
2024-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting |
Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerations BOSTON and MONTREAL , May 2, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced an oral presentation at the American Urology Association (AUA) 2024 Annual Meeting being held May 3-6, 2024 in San Antonio, Texas. The presentation, "LEGEND: a Phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS)," will be given by Dr. Gordon Brown, Director of the Center for Advanced Therapeutics and Urologic Oncology, Summit Health-South, at 10:30 a.m. |
prnewswire.com |
2024-05-02 20:05:00 |
Czytaj oryginał (ang.) |
| /C O R R E C T I O N -- enGene Inc./ |
In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by enGene Inc., the headline was incorrectly transmitted by CNW. The headline should read "enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development". |
prnewswire.com |
2024-04-09 12:56:00 |
Czytaj oryginał (ang.) |
| enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress |
Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) remains on track with interim data anticipated in mid-2024 Closed a $200 million oversubscribed private financing, expected to extend cash runway into 2027 BOSTON and MONTREAL , March 11, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024. "This is an exciting time for the Company as we move closer to realizing our vision of mainstreaming genetic medicines to address diseases with high unmet clinical needs. |
prnewswire.com |
2024-03-11 19:16:00 |
Czytaj oryginał (ang.) |
| enGene To Present at the Leerink Partners Global Biopharma Conference |
BOSTON and MONTREAL , March 5, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on March 13, 2024, at 8:40 a.m. ET. A live webcast of the presentation can be accessed under the Investors section of the enGene website at www.engene.com/presentations and will be archived there for 90 days. |
prnewswire.com |
2024-03-05 09:00:00 |
Czytaj oryginał (ang.) |